Why Should We Fund The SSC?

Projects, Anyway? AUTHOR: Jeffrey Mervis, p.11,13. Twice in a recent eight-day span, the United States House of Representatives debated the proper balance between "big" and "little" science. In both cases, big science won. The debates preceded separate votes on appropriations bills for fiscal year 1992. Although the bills include proposed funding for such items as low-income housing and federal water projects, most of the more than 10 hours spent discussing them centered on the value of two meg

Written byJeffrey Mervis
| 12 min read

Register for free to listen to this article
Listen with Speechify
0:00
12:00
Share

Projects, Anyway?

AUTHOR: Jeffrey Mervis, p.11,13.

Twice in a recent eight-day span, the United States House of Representatives debated the proper balance between "big" and "little" science. In both cases, big science won.

The debates preceded separate votes on appropriations bills for fiscal year 1992. Although the bills include proposed funding for such items as low-income housing and federal water projects, most of the more than 10 hours spent discussing them centered on the value of two megascience projects: the Energy Department's superconducting supercollider (SSC) and the National Aeronautics and Space Administration's Freedom space station.

In both cases, the underlying issue was the comparative payoffs of the two undertakings, in particular, whether these multibillion-dollar efforts are worth the cost and what effect they will have on hundreds of other projects that enhance the human condition. Resolution of the matters stands to impact the professional futures of thousands of working scientists.

...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies